INTRODUCTION
The motheaten (me/me) mouse was first described by Green and Shultz in 1975 as a spontaneous autosomal recessive mutation leading to immune deficiency, widespread inflammation, and death at 2 to 4 weeks of age (Green and Shultz, 1975) . Later, a related mutant strain was discovered (motheaten viable, or me v /me v ) in which the homozygous mice display a similar, though less severe, phenotype and survive for several more (9-12) weeks (Shultz et al., 1984) . Both lines of mice exhibit chronic inflammation of the skin (leading to fur loss, hence the name ''motheaten''), accompanied by the production of autoantibodies and immune complex deposition in tissues. me/me and me v /me v mice also develop a lethal pneumonitis characterized by neutrophil and macrophage accumulation in the lungs (Jiao et al., 1997) . Gene-mapping studies show that distinct mutations in Ptpn6, which encodes the protein-tyrosine phosphatase Shp1, cause the me/me and me v /me v phenotypes.
The Ptpn6 me/me mutation results in complete loss of Shp1 protein, whereas Ptpn6 me-v/me-v mice express wild-type (WT) amounts of two mutant forms of Shp1 with greatly reduced catalytic activity , both of which have milder phenotypes than seen in Ptpn6 me-v/me-v mice (Croker et al., 2008; Nesterovitch et al., 2011a) . The motheaten phenotype has long served as a paradigm for a complex autoimmune and inflammatory disease; therefore, elucidating its pathogenesis is of general interest. Substantial effort has been devoted to investigating the function of Shp1 in the immune system (Pao et al., 2007a; Tsui et al., 2006) . Nevertheless, its detailed role in WT mice, and an understanding of how Ptpn6 mutations cause autoimmunity and inflammation, remains unclear. All hematopoietic cells express Shp1, and their complicated interactions have made it difficult to dissect the relative contributions of different cell types to motheaten disease. Transplantation experiments indicate that the motheaten phenotype is due predominantly to bone-marrowderived cells. Moreover, pretreatment of motheaten mice with anti-CD11b prevents the development of skin inflammation, pneumonitis, splenomegaly, and defective T cell function (Koo et al., 1993) . These data indicate that myeloid cells not only cause the inflammatory disease but also influence the development of autoimmunity in motheaten mice. Consistent with this conclusion, analysis of Ptpn6 me-v/me-v mice on a Rag1-deficient background shows that B and T lymphocytes are dispensable for the inflammatory disease (Yu et al., 1996) . In addition to acting in several hematological cell types, Shp1 is implicated in the regulation of multiple signaling pathways, including those downstream of integrins, receptor tyrosine kinases, G protein coupled receptors, Toll-like receptors (TLRs), and cytokine receptors (Neel et al., 2003; Pao et al., 2007a; Zhang et al., 2000) . Much previous work has focused on studying cells isolated from mice containing Ptpn6 mutations. 
Itgax-cre Mice
(A and C) Mice of the indicated genotypes were monitored every two (Ptpn6 fl/fl S100a8-cre) or four (Ptpn6 fl/fl Itgax-cre) weeks for paw inflammation or lymphadenopathy, respectively. The presence of these phenotypes was scored, and the percentage of ''disease-free'' mice at each time point was graphed using Prism, ***p < 0.001.
(legend continued on next page)
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Immunity Deconvoluting the Phenotype of motheaten Mice reflecting an inability to de-adhere due to exaggerated integrin signaling (Kruger et al., 2000) . Macrophages from Ptpn6 me-v/me-v mice also are hyperadhesive to integrin ligands and are hyperresponsive to colony-stimulating factor-1 (CSF-1) and granulocyte-macrophage colony stimulating factor-1 (GM-CSF) (Chen et al., 1996; Jiao et al., 1997; Roach et al., 1998) . In dendritic cells (DCs), Shp1 reportedly regulates multiple TLR and cytokine signaling responses (An et al., 2008; Ramachandran et al., 2011) . In general, myeloid cells lacking Shp1 are hyperresponsive to multiple stimuli, but it is unclear which stimuli, acting in which cell types, are critical to the development of the motheaten phenotype. Furthermore, alterations in immune cell function might arise as a consequence of indirect effects caused by the inflammatory milieu in these animals, rather than from cell-intrinsic abnormalities caused by loss of Shp1 function. The development of a conditional (floxed) Ptpn6 allele (Pao et al., 2007b) has facilitated investigation of the roles of specific cell types in the pathogenesis of the motheaten phenotype. Mice lacking Shp1 in B cells show perturbed B cell development, specifically an expansion of B1a cells at the expense of B2 cells, and aberrant B cell receptor signaling in B1a cells. These mice develop autoimmune disease, but they do not develop the inflammatory skin or lung disease characteristic of motheaten mice (Pao et al., 2007b) . Mice lacking Shp1 in T cells develop neither autoimmunity nor inflammatory disease (Fowler et al., 2010) . In this study, we investigated the contribution of specific myeloid cell subsets to the motheaten phenotype by crossing Ptpn6 fl/fl mice with mice that express Cre in distinct lineages of myeloid cells. Our results provide insights into the pathogenesis of the motheaten phenotype and provide a molecular framework for understanding the complex interactions between immune cells that drive autoimmune and inflammatory diseases.
RESULTS
Specificity of Myeloid Cre Deletion
We set out to determine the contribution of Shp1-deficient myeloid cells to the motheaten phenotype by crossing Ptpn6 fl/fl mice to several myeloid Cre lines. To assess the efficiency and specificity of deletion, we also crossed each Cre line to ROSA26-lox-stop-lox-EYFP reporter (ROSA-YFP) mice, and then quantified the percentage of YFP + cells by flow cytometry.
In Vav1-cre:ROSA-YFP mice, all hematopoietic cells analyzed were 98%-100% YFP + (data not shown). S100a8 (also known as MRP8)-cre:ROSA-YFP mice showed specific deletion in neutrophils, with little or no YFP expression in macrophages, monocytes, NK cells, mast cells, basophils, or eosinophils (data not shown). As the S100a8-cre transgene contains an IRES-GFP cassette, we also followed Cre expression by flow cytometry; these data confirmed that in Ptpn6 fl/fl S100a8-cre and Ptpn6 +/+ S100a8-cre mice, the Cre transgene was expressed only in mature and immature neutrophils (see Figure S1A available online). Furthermore, intracellular staining by flow cytometry revealed an absence of Shp1 in neutrophils from Ptpn6 fl/fl S100a8-cre and Ptpn6 fl/fl Vav1-cre mice ( Figure S1B ).
Ptpn6
+/+ and Ptpn6 fl/fl S100a8-cre mice showed equivalent Shp1 expression in all other hematopoietic cell types (data not shown). Biochemical analysis of neutrophils isolated from bone marrow confirmed that Ptpn6 fl/fl S100a8-cre neutrophils expressed $20% of the WT amount of Shp1 ( Figure S1C S100a8-cre mice developed spontaneous paw inflammation beginning at 8-12 weeks of age, which was 85% penetrant on a mixed 129Ola;C57BL/6 background and fully penetrant on the C57BL/6 background ( Figure 1A ). Histological analysis of the inflamed paws showed thickened dermal and epidermal layers and bone-marrow hypercellularity ( Figure 1B ). The dermal inflammation peaked at 8-10 weeks and then partially, but never completely, resolved, suggesting that the mice were able to control the neutrophil hyperactivity to some extent. The histology of the dermal inflammation in the paws of Ptpn6 fl/fl S100a8-cre mice matched that seen in Ptpn6 fl/fl Vav1-cre and Ptpn6 me-v/me-v mice (data not shown).
(B) H&E-stained sections of normal and inflamed paws from WT S100a8-cre or Ptpn6 fl/fl S100a8-cre mice. Original magnification was 310 (top) and 340 (bottom).
Thickened epidermal and dermal layers are indicated by blue and black arrowheads, respectively; bone-marrow hypercellularity is indicated by the asterisk. Itgax-cre mice. Original magnification was 320. Data were pooled from six independent experiments. See also Figure S1 .
By contrast, Ptpn6
fl/fl Itgax-cre mice did not exhibit paw inflammation, but instead, developed lymphadenopathy, which began at $15 weeks of age ( Figure 1C ) and became fully penetrant by 40 weeks ( Figure 1D ). All Ptpn6 fl/fl Itgax-cre mice had splenomegaly at 40 weeks of age ( Figure 1E ), and these mice also developed anti-nuclear antibodies (Figures 1F and 1G) and glomerulonephritis ( Figure 1H ). Ptpn6 fl/+ Itgax-cre mice showed an intermediate degree of splenomegaly, but not lymphadenopathy, at 40 weeks of age ( Figures 1D and 1E ) and also developed anti-nuclear antibodies (data not shown). Thus, even heterozygous deficiency of Shp1 in DCs was sufficient to cause some degree of autoimmunity. Notably, at no time did Ptpn6 fl/fl S100a8-cre mice show any evidence of autoimmune disease.
Neither neutrophil-nor DC-specific deletion of Ptpn6 caused the lethal inflammatory lung disease observed in motheaten and motheaten viable mice. Although blinded histological analysis of lung sections showed that some Ptpn6 fl/fl S100a8-cre and Ptpn6 fl/fl Itgax-cre animals had diffuse or patchy inflammatory cell infiltrates in their lungs, these were mild ( Figure S1G ). Even combined deficiency of Shp1 in neutrophils, alveolar macrophages and DCs (i.e., in Ptpn6 fl/fl S100a8-cre;Itgax-cre mice) failed to induce diffuse inflammatory lung disease. By contrast, Ptpn6 fl/fl Vav1-cre mice exhibited the same diffuse lung inflammation seen in motheaten strains and died within weeks of birth.
The increase in splenocyte number was modest in Ptpn6
S100a8-cre mice, compared with that seen in Ptpn6 fl/fl Itgaxcre animals ( Figure 2A ). By 15-20 weeks of age, Ptpn6 fl/fl S100a8-cre mice had moderately increased numbers of splenic and bone-marrow neutrophils compared with controls (Figure 2B) and no alterations in splenic T or B cell numbers or activation status ( Figure 2E ; data not shown). By contrast, spleens from Ptpn6 fl/fl Itgax-cre mice showed disrupted architecture, with a loss of germinal centers and blurring of the border between the white and red pulp ( Figure 2C ). Splenomegaly in these mice was caused by increased numbers of both myeloid and lymphoid cells (Figures 2D and 2E) . The numbers of cDCs and pDCs were increased, and both showed significant activation, as indicated by upregulation of CD86 and major histocompatibility complex class II glycoproteins (MHCII), respectively (Figures 2F and 2G) . Ptpn6 fl/fl Itgax-cre mice also showed dramatic increases in CD4 + T lymphocytes and in several B cell subsets (Figures S2A and S2D) . Their T cells showed upregulation of the early activation marker CD69, and there also was an expansion of the effector and memory CD44 hi CD62L lo T cell compartment (Figures S2B and S2C) . Follicular B cells showed upregulation of MHCII and CD86 ( Figure S2E ; data not shown).
We also analyzed a group of Ptpn6 fl/fl Itgax-cre mice at 8-11 weeks of age, before signs of autoimmunity were apparent. Spleen cell numbers were not increased significantly at this time, but DC activation was present, indicating that the latter precedes the development of autoimmune disease ( Figure S2F ). Analysis of peripheral blood samples from Ptpn6 fl/fl Itgax-cre mice revealed a dramatic expansion of the CD11b + compartment, compared with controls or Ptpn6 fl/fl S100a8-cre mice, that was concomitant with a gradual increase in anti-nuclear and anti-dsDNA antibody titers ( Figures S2G-S2K ). We also measured cytokine concentrations in the sera from both groups of mice using multiplex bead analysis. Not surprisingly, by 30 weeks of age, Ptpn6 fl/fl Itgax-cre mice showed elevated concentrations of all cytokines examined, reflecting the general cell expansion and immune cell activation in these animals (Figure S2L) . By contrast, only G-CSF was increased in the sera of 16-to 20-week-old Ptpn6 fl/fl S100a8-cre mice, compared with controls, which likely accounts for the increased number of immature granulocytes in the spleens of these animals (Figures S1A and S2M). Sera from Ptpn6 fl/fl Itgax-cre mice at the same age showed elevated concentrations of cytokines, similar to those observed at 30 weeks of age (data not shown). At earlier times, which coincided with peak paw inflammation, Ptpn6
S100a8-cre mice also had higher concentrations of keratinocyte-derived cytokine (KC), IL-6, and macrophage inflammatory protein-1a (MIP-1a) ( Figure S2N ).
Inflammation in Motheaten Mice Is Caused by Abnormal Integrin Signaling in Neutrophils
Previous work suggests that increased IL-1b signaling in neutrophils is a major contributor to inflammation in the motheaten mouse (Croker et al., 2008) . Because IL-1b signaling is mediated through the MyD88 adaptor protein, we tested the role of this pathway by crossing motheaten viable mice with Myd88 À/À animals but, surprisingly, failed to obtain any live progeny. We also failed to generate any live Ptpn6 fl/fl Myd88 fl/fl Vav1-cre mice, although we did obtain expected numbers of day 17 embryos with that genotype (Figure S3A ). These data indicate that combined Shp1 and MyD88 deficiency causes some uncharacterized defect in late embryonic development. However, Ptpn6 fl/fl Myd88 fl/fl S100a8-cre mice (i.e., mice with Shp1 and MyD88 deficiency restricted to neutrophils) exhibited the same inflammatory disease as Ptpn6 fl/fl S100a8-cre mice ( Figure 3A ). Further analysis of double-mutant mice showed that neutrophil-specific deletion of Myd88 did not reverse the increase in spleen size or splenocyte number seen in Ptpn6 fl/fl S100a8-cre animals ( Figures S3B  and S3C ). There also was no significant decrease in the number of splenic neutrophils compared to Ptpn6 fl/fl S100a8-cre mice ( Figure S3E ). Deletion of Myd88 in neutrophils did, however, reduce the increase in bone-marrow cellularity found in Ptpn6 fl/fl S100a8-cre mice ( Figures S3D and S3E ). These data indicate that the inflammation caused by deficiency of Shp1 in neutrophils does not result from excessive signaling through MyD88-dependent pathways. Consistent with this notion, there was no difference in lipopolysaccharide (LPS)-or Pam3CSK4-evoked p38 MAPK phosphorylation in Shp1-deficient neutrophils ( Figure S3F ). Similarly, fMLF-or C5a-stimulated Erk phosphorylation, G-CSF-stimulated Stat3 phosphorylation and GM-CSF-stimulated Stat5 phosphorylation were unaffected or slightly hyporesponsive ( Figure S3G ). These results suggest that Shp1 is not a major regulator of TLR, G protein-coupled, or cytokine receptor responses in neutrophils and that these pathways do not initiate the motheaten inflammatory phenotype. Neutrophils from motheaten mice are hyperresponsive to integrin stimulation (Kruger et al., 2000) , so we asked whether loss of Shp1 function downstream of integrin signaling might contribute to inflammatory dermatitis. Indeed, compared with controls, neutrophils from Ptpn6 fl/fl S100a8-cre mice produced more superoxide when plated on pRGD (which engages b1 and b2 integrins on these cells) in the presence or absence of tumor necrosis factor-a (TNF-a) ( Figure 3B ). We also observed enhanced activation-specific phosphorylation of Erk ( Figure 3C ) and Src-family kinases (SFKs; Figure 3D ) in neutrophils from Ptpn6 fl/fl S100a8-cre mice plated on integrin ligands. No difference in the expression of SFKs was observed in neutrophils from these mice ( Figure S3H ). These data suggested that Shp1 might regulate integrin signaling in neutrophils by influencing SFK activity.
Previous work from our group has shown that Syk is required for neutrophil integrin signaling (Mó csai et al., 2002). We hypothesized that deletion of Syk in neutrophils would reverse the inflammatory disease in found Ptpn6 fl/fl S100a8-cre mice. We tested this by generating Ptpn6 fl/fl Syk fl/fl S100a8-cre mice, which lack both Shp1 and Syk specifically in neutrophils. Remarkably, these mice were completely free of paw inflammation (Figure 4A) and showed normal numbers of spleen and bone marrow neutrophils ( Figures 4B-4E ). Neutrophils from these mice showed reduced superoxide production ( Figure 4F ) and normal Erk activation upon plating on integrin ligands ( Figure 4G ), compared to neutrophils from Ptpn6 fl/fl S100a8-cre mice. These data indicate that loss of Syk in neutrophils alone prevents the motheaten inflammatory phenotype by reducing signaling Itgax-cre mice. Each bar represents an n of 5-10 mice at 15-20 weeks of age per group (error bars indicate SEM). *p < 0.05, **p < 0.01, ***p < 0.001. Data were pooled from six independent experiments. See also Figure S2. downstream of integrins. SFKs also are critical for the initiation of integrin signaling in neutrophils (Pereira and Lowell, 2003; Suen et al., 1999) , and we observed reversal of motheaten inflammatory disease in Ptpn6 me-v/me-v mice that also lacked the SFKs Hck and Fgr or Hck, Fgr, and Lyn (data not shown). We conclude that the inflammatory phenotype in motheaten mice primarily results from dysregulated neutrophil integrin signal transduction due to increased SFK and Syk activity. and 5B), and sera from these mice lacked antinuclear ( Figure 5C ) or anti-DNA ( Figure 5D ) antibodies. These mice also showed significant reductions in splenic plasma cell numbers and T cell activation, and a striking reduction in myeloid expansion ( Figures 5E-5G ). The number and activation status of both cDCs and pDCs in these mice were reduced (Figure 5H ). Immunoblot analysis confirmed that the amounts of Shp1 and MyD88 protein were reduced in DCs from spleens of Ptpn6 fl/fl Myd88 fl/fl Itgax-cre mice ( Figure S4 ). These data indicate that loss of MyD88 in DCs prevents motheaten autoimmune disease by blocking autoantibody production and preventing T cell activation and myeloid expansion.
Autoimmunity in
Previous studies have reported that Shp1 is a negative regulator of TLR signaling in macrophages and DCs (Hardin et al., 2006; Ramachandran et al., 2011) . Indeed, BMDCs from Ptpn6 fl/fl Vav1-cre mice showed enhanced phosphorylation of Erk and NF-kB (p65) and increased TNF-a production following LPS stimulation ( Figure 6A ; Figures S5C and S5D ). We also observed increased total, as well as Syk and SFK, tyrosine phosphorylation in Shp1-deficient DCs ( Figure S5A ). The Shp1 substrate Sirpa also was hyperphosphorylated in Shp1-deficient BMDCs ( Figure S5B ). Importantly, these abnormalities were reversed by reexpression of Shp1, indicating that they reflect effects of Shp1 deficiency on signaling per se, rather than potential indirect effects of the floxed Ptpn6 allele on adjacent genes or DC development ( Figures S5B-S5D ). Because our genetic evidence suggested that dysregulation of MyD88-mediated pathways in DCs underlies the autoimmune disease caused by Shp1 deficiency in these cells, we examined TLR signaling responses in cells from Ptpn6 fl/fl Itgax-cre mice. Splenic DCs lacking Shp1 showed dramatically enhanced Erk activation in response to LPS or CpG stimulation ex vivo ( Figure 6B) . Hyperactivation of the Erk pathway in Shp1-deficient DCs correlated with an increase in TNF-a production induced in these cells in response to either TLR agonist ( Figure 6C ). By contrast, GM-CSF-stimulated Stat5 phosphorylation and IL-6-stimulated Stat3 phosphorylation were unaffected, or even mildly hyporesponsive ( Figures S5E and S5F) . Moreover, LPS signaling responses were normalized in splenic DCs from Ptpn6 fl/fl Myd88 fl/fl Itgax-cre mice ( Figures 7A and 7B ). We S100a8-cre, n = 9) were monitored for paw inflammation, and the percentage of disease-free mice at each time point was graphed using Prism, ***p < 0.001. (B) Spleen weights, relative to total mouse weight, for the indicated genotypes; each circle represents a single mouse, ***p < 0.001. (C-E) Spleen and bone-marrow cells from mice of the indicated genotypes were harvested, counted by using a nucleocounter, then stained with fluorescently conjugated antibodies and analyzed by flow cytometry. Each circle represents a single mouse. Bars represent the average of 9-17 mice per group (error bars indicate SEM). *p < 0.05, **p < 0.01, ***p < 0.001. (F) Neutrophils isolated from mice of the indicated genotypes were plated onto the integrin ligand pRGD in the presence or absence of TNF-a, and superoxide release was measured (error bars indicate SEM). (G) Neutrophils from WT C57BL/6, Ptpn6 fl/fl S100a8-cre, and Ptpn6
fl/fl
Syk fl/fl S100a8-cre mice were kept in suspension or plated onto pRGD-coated plates for 15 min, lysed, and analyzed by SDS-PAGE, followed by immunoblotting with the indicated antibodies. Data shown in (F) and (G) are representative of at least three individual experiments.
conclude that Shp1-mediated regulation of TLR signaling pathways in DCs is an important factor in the development of autoimmune disease in motheaten mice.
DISCUSSION
We have determined the respective contributions of neutrophils and DCs to the complex disease phenotype in motheaten mice. We found that deficiency of Shp1 in neutrophils is sufficient to cause spontaneous skin inflammation, whereas Shp1-deficiency in DCs leads to severe autoimmunity. The autoimmune phenotype observed upon deletion of Ptpn6 in DCs provides one of the first examples that dysregulation of this single innate immune cell type can cause autoimmune disease (see also Kaneko et al., 2012) . We also identified key, and distinct, signaling pathways important for the Shp1-deficient phenotype in each of these cell types. Shp1 has been implicated in the regulation of multiple signaling cascades, so one might expect that Shp1 deficiency would cause global activation of many cellular pathways. Surprisingly, we found that this was not the case; instead, inflammation and autoimmunity in this model result from aberrant activation of integrin signaling in neutrophils and TLR signaling in DCs. Several lines of evidence indicate that the spontaneous skin inflammation observed upon specific deletion of Ptpn6 in neutrophils is due to hyperactive integrin signaling. For example, we saw enhanced activating phosphorylation of SFKs and the MAPKs Erk 1 and 2 in response to integrin ligation, as well as increased superoxide production by neutrophils plated onto integrin ligands. Most importantly, neutrophil-specific deletion of Syk, a critical mediator of integrin signals, prevented hyperactive integrin signaling in Ptpn6 fl/f S100a8-cre neutro- S100a8-cre animals, demonstrating that neutrophil-mediated inflammation was not driven by hyperactivation of neutrophil-intrinsic TLR or IL-1b signaling through MyD88. Our results differ from the conclusions of earlier work using Ptpn6 spin/spin mice, which were obtained by ENU-induced (C) Splenocytes were harvested from mice of the indicated genotypes, treated with brefeldin A, and stimulated with 1 mg/ml LPS or 2 mg/ml CpG for 5 hr. Cells were fixed and stained with fluorescently labeled anti-TNF-a and anti-CD11c, and analyzed by flow cytometry. Data in (B) and (C) are representative of three independent experiments done on different cohorts of mice. See also Figure S5 .
mutagenesis of C57BL/6J mice and contain a Y208N amino acid substitution in the C-terminal SH2 domain of Shp1. Spontaneous paw inflammation does not occur when these mice are crossed with Myd88 poc/poc mice (Croker et al., 2008) , and inflammatory disease in Ptpn6 spin/spin mice has been attributed to hyperactive IL-1b signaling in neutrophils (Croker et al., 2011) . There are several possible reasons for the apparent contradiction between our conclusions and those of Croker and colleagues. First, we specifically removed Shp1 from neutrophils using S100a8-credirected deletion. Conceivably, indirect effects of other cells on neutrophils could explain the earlier findings, because the Ptpn6 spin/spin mutation is present in all cells. Second, the Ptpn6 spin/spin mutation results in a Shp1 protein containing a nonfunctional SH2 domain, whereas Ptpn6 fl/fl S100a8-cre mice have a complete absence of Shp1. Finally, Croker et al. used a point mutant of MyD88 that reduces signaling, whereas we used mice that lacked MyD88 completely.
The fact that these studies produced such different results might highlight the roles of individual domains of Shp1 in immune cell function. Shp1 reportedly has phosphatasedependent and -independent functions (An et al., 2008) , so different mutants might have diverse effects on cell signaling. Indeed, we showed previously that some Shp1 substrates are hyperphosphorylated in cells from Ptpn6 me-v/me-v mice, wherein Shp1 is present but has reduced phosphatase activity, but hypophosphorylated in Ptpn6 me/me cells, which lack Shp1 expression (Timms et al., 1998) . A point mutation affecting an SH2 domain but leaving the phosphatase domain intact might well act differently than a mutation that leads to complete loss of Shp1.
In contrast to Ptpn6 fl/fl S100a8-cre mice, Ptpn6 fl/fl Itgax-cre mice showed a dramatic expansion of myeloid cells and an increase in serum cytokines. These alterations impacted the WT lymphoid compartment, in which Shp1 continued to be expressed at WT amounts, leading to T and B cell activation and plasma cell expansion. Ptpn6 fl/+ Itgax-cre mice also developed autoimmune disease, consistent with previous observations that Ptpn6 me-v/+ mice produce autoantibodies (Kuntz et al., 1990) . As in neutrophils, Shp1 deficiency in DCs did not cause global activation of multiple signaling pathways; instead, splenic DCs from Ptpn6 fl/fl Itgax-cre mice were hyperresponsive specifically to TLR ligands, including LPS and CpG. This enhancement of TLR signaling is critical for autoimmunity, because simultaneous deletion of Myd88 prevented disease development in these mice. Autoimmune disease traditionally has been attributed to altered B or T cell function, but our findings indicate that dysregulation of DC-intrinsic TLR signaling alone can drive disease. Similarly, DC-specific deletion of A20, a negative regulator of NF-kB signaling, reportedly leads to autoimmunity (Kool et al., 2011) , although this finding is controversial (Hammer et al., 2011) . The ability of TLR signaling to drive autoimmunity is consistent with the fact that human autoimmune disease often is exacerbated by concurrent infections that could provide signals through TLRs (Chervonsky, 2010; Marshak-Rothstein, 2006) . Our report demonstrates that exaggerated TLR signaling in DCs alone can drive autoimmune disease development.
How Shp1 Ramachandran et al., 2011; Rego et al., 2011; Zhou et al., 2010) . These studies are complicated, if not compromised, by cell-type specificity and the variety of different Shp1 mutations used. Furthermore, experiments exploring the effects of acute Ptpn6 deletion could highlight aberrant signaling pathways that can be compensated for in cells with chronic Shp1 deficiency. For example, LPS-treated bone-marrow-derived macrophages from Ptpn6 me-v/me-v mice produce WT amounts of TNF-a and IL-6, but less IL-12p40 (Zhou et al., 2010) , whereas the same cells isolated from Ptpn6 me/me mice produce more TNF-a, but less IL-6 (Rego et al., 2011) . Peritoneal macrophages from Ptpn6 spin/spin mice show no change in TNF-a production in response to TLR ligands, in contrast to the neutrophils from these animals, which produce increased levels of TNF-a (Croker et al., 2008; Croker et al., 2011) . Furthermore, WT BMDCs subjected to three independent methods of acute Shp1 inhibition produce elevated IL-12p70, IL-1b, and IL-6, but not TNF-a following LPS treatment (Ramachandran et al., 2011) . The authors of this study further noted that BMDCs from Ptpn6 me-v/me-v mice are less responsive to LPS, showing that different results are observed depending on how Shp1 is inactivated. Shp1 has been proposed to inhibit TLR signals in a phosphatase-dependent manner by dephosphorylating IRAK4 (Ramachandran et al., 2011) or by inhibiting PI-3 kinase (Zhou et al., 2010) and in a phosphatase-independent way by binding to and inhibiting the kinase domain of IRAK1 (An et al., 2008) . These studies highlight that the precise mechanism by which Shp1 modulates TLR responses remains confusing; nevertheless, our results clearly demonstrate that this regulation is physiologically significant, especially in DCs. In our study, deletion of Ptpn6 in neutrophils or alveolar macrophages (afforded by the Itgax-cre transgene) or both was not sufficient to cause major cellular infiltration into the lung, even though both of these cell types are found in the lungs of motheaten mice. Presumably, pneumonitis requires Shp1 deficiency in other cell types. Other lung diseases are dependent on platelets (Looney et al., 2009) , so their contribution to pulmonary disease in the motheaten model merits future investigation. Similarly, the contribution of mast cells should be considered, given the partial rescue of the lung phenotype in motheaten mice crossed onto a mast cell-deficient background such as (Lorenz et al., 1996; Paulson et al., 1996; Zhang et al., 2010) . Previous work also has shown that pulmonary inflammation in Ptpn6 me-v/me-v mice is significantly ameliorated by concomitant IL-13 or Stat6 deletion, but the cell type involved is unknown (Oh et al., 2009) .
Our results, combined with previous reports on the effects of B cell-and T cell-specific Ptpn6 deletion, provide a much improved understanding of the relative contributions of different hematopoietic cells to the overall motheaten phenotype (Fowler et al., 2010; Pao et al., 2007b) . Future work will be required to dissect the specific molecular interactions, including cytokine networks, between these cells and their contribution to the complex disease present in motheaten mice. Given the recent observation of mutations in Ptpn6 in human neutrophilic dermatoses that mimic the inflammatory disease seen in motheaten mice (Nesterovitch et al., 2011b) , and the emerging causal role of DCs in autoimmune disease, understanding how Shp1 functions in different cell types should provide insights into developing targeted therapies to treat human inflammatory and autoimmune disease.
EXPERIMENTAL PROCEDURES
Mice and Reagents Details of mouse strains used can be found in Supplemental Experimental Procedures. All mice were kept in a specific pathogen-free facility at the University of California, San Francisco (UCSF), and cared for in accordance with UCSF institutional guidelines.
Cell Preparation and Flow Cytometry
Single cell suspensions were prepared by homogenizing spleens between two frosted microscope slides, followed by passage through a 70 mM cell strainer. Cell numbers were determined by using a Nucleocounter (Chemometec). Peripheral blood was collected in microtainer tubes with EDTA (BD Biosciences), and CBCs were obtained by using a Hemavet 950 (Drew Scientific). Bronchoalveolar lavage cells were obtained with five 1 ml flushes of the lungs with ice-cold 5 mM EDTA in PBS. Peritoneal lavage cells were obtained with a 10 ml flush of the peritoneum with ice cold 2% (vol/vol) FCS in PBS. Red blood cells were removed from all cell suspensions by lysis with ACK buffer (150 mM NH 4 Cl, 10 mM KHCO 3 , 0.1 mM EDTA pH 7.2-7.4). Bonemarrow cell suspensions were obtained by flushing femurs and tibiae, lysing red blood cells with a hypotonic NaCl solution, and passage through a 70 mM cell strainer. Cells were resuspended in Hanks-buffered saline solution containing 2% (vol/vol) fetal calf serum, 20 mM HEPES, and 1 mM EDTA and maintained at 4 C. For flow cytometry, 1-2 3 10 6 cells were stained. Nonspecific binding was blocked by preincubation with 0.5 mg anti-CD16/32 (2.4G2, UCSF Immunology Hybridoma Core) and 100 mg mouse IgG (Sigma). For intracellular staining of Shp1, spleen or bone-marrow cells, stained for the above surface markers, were incubated with Cytofix/Cytoperm (BD Biosciences), blocked with 2.4G2 and murine IgG as before, stained with anti-Shp1-PE (Santa Cruz Biotechnology), washed with Perm/Wash (BD Biosciences), and analyzed by flow cytometry.
For phosphoflow experiments, bone-marrow cells or splenocytes were resuspended in 10% (vol/vol) FCS in RPMI at 2 3 10 6 cells/ml and incubated for 1 hr at 37 C, 5% CO 2 . Stimuli were added for the indicated times, and then cells were fixed with 1.5% (vol/vol) methanol-free formaldehyde (Thermo-Scientific) at RT for 15 min, followed by permeabilization in icecold methanol for 15-30 min on ice or overnight at À80 C. Fixed cells were washed with 0.5% (wt/vol) BSA, 0.02% (wt/vol) NaAz in PBS, blocked with 2.4G2 and murine IgG as before and stained with the following antibodies in addition to those listed in the Supplemental Experimental Procedures: antiphospho-Erk (Cell Signaling Technology), donkey anti-rabbit IgG-APC (Jackson Laboratories), anti-phospho Stat3-FITC, and anti-phospho Stat5-FITC (BD Biosciences). For intracellular cytokine staining, splenocytes were resuspended in 10% (vol/vol) FCS in RPMI at 2 3 10 6 cells/ml and stimulated with 1 mg/ml LPS or 2 mg/ml CpG for 5 hr at 37 C, 5% CO 2 in the presence of 10 mg/ml Brefeldin A (eBiosciences). Fixed cells were washed and stained for surface markers as above in the presence of Brefeldin A, then incubated in Fixation/Permeabilization Concentrate diluted 1:4 with Diluent solution (eBiosciences). Cells were blocked with 2.4G2 and murine IgG, stained with anti-TNF-a-FITC (eBiosciences), washed with Permeabilization buffer (eBiosciences), and analyzed by flow cytometry. CD11c hi splenic DCs were purified with a PE conjugated anti-CD11c followed by anti-PE microbeads (Miltenyi Biotec). The positive fraction was eluted using Miltenyi Biotec columns, stained as described above, and sorted on a FACs Aria (Becton Dickinson) to >95% purity. CD11c + splenic DCs were purified using the mouse CD11c + selection kit (StemCell Technologies).
Histology
Tissues were fixed in 10% (vol/vol) formalin, embedded in paraffin and stained with hematoxylin and eosin by the UCSF Pathology core. Paws were fixed in 10% (vol/vol) buffered formalin solution (Sigma) for 2 days, rinsed with tap water, incubated in Cal-Ex (Fisher Scientific) for 2-3 days, and cut longitudinally before being processed as above.
Detection of Serum Anti-Nuclear Antibodies and Cytokines
Blood was collected in Z-gel microtubes (Sarstedt) and left to clot at RT for 30-45 min. Then, tubes were centrifuged at 6,000 3 g for 2 min to obtain serum. Sera were diluted 1:40 and applied to Kallestad HEp-2 slides (BioRad). Anti-nuclear antibodies were detected using FITC conjugated goat anti-mouse IgG (Jackson ImmunoResearch Laboratories). For ANA quantification, Adobe Photoshop was used to determine mean pixel intensity in the green channel. For anti-dsDNA Ig ELISA, 96-well flat-bottom polystyrene plates (Microtest 351172, BD) were coated with 20 ng/well of linearized pUC19 plasmid in 100 mM Tris-HCl. After overnight incubation at room temperature, plates were blocked with PBS containing 2% (vol/vol) FCS and 0.05% (vol/vol) Tween 20 for 30 min. Sera, diluted 1:40-1:600, were added to the plate and incubated for 2 hr at room temperature. The assays were developed with horseradish-peroxidase-conjugated goat anti-mouse IgG (1:3,000) or IgM (1:5,000) (Bethyl Laboratories). After addition of TMB Microwell Peroxidase Substrate System (KPL), reactions were terminated with 1 M phosphoric acid (Sigma-Aldrich), and the absorbance at 450 nm (A 450 ) was measured by using a Spectra Max Plus microplate reader (Molecular Devices). Cytokine and chemokine concentrations in mouse sera were quantified using a MilliplexÒMAP mouse cytokine and chemokine kit from Millipore, according to the manufacturer's instructions. The concentration of TNF-a in BMDC culture supernatants was determined by ELISA (R&D Systems).
Cellular Functional Assays and Biochemical Analysis
Neutrophils, purified from bone marrow as described previously (Mó csai et al., 2002 (Mó csai et al., , 2006 or by using a five-step gradient (Siemsen et al., 2007) , were stimulated as described (Mó csai et al., 2002 (Mó csai et al., , 2006 . Adhesion-dependent respiratory burst was measured as reported previously (Mó csai et al., 2002) or by using isoluminol-enhanced chemiluminescence (Dahlgren et al., 2007) . Bone-marrow-derived macrophages were differentiated in vitro from mononuclear cells as described (Mó csai et al., 2006) . BMDCs were differentiated in vitro from mononuclear cells cultured for 11 days in medium containing GM-CSF. Cells were serum-starved for 12 hr prior to stimulation. Bone-marrow mononuclear cells were spin-infected with retrovirus as described (Mó csai et al., 2006) , followed by differentiation in medium containing GM-CSF.
Statistical Analyses
Statistical analyses were carried out using GraphPad Prism. The percentage of disease-free mice was plotted by using Kaplan-Meir survival analysis and analyzed by using a log-rank (Mantel-Cox) test. Differences between two groups were assessed by the unpaired t test; differences between three or more groups were evaluated by ANOVA, followed by Bonferroni's Multiple Comparison post-test. Differences between observed and expected allele frequencies were evaluated by c 2 test. Differences were considered significant when p % 0.05.
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